Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.
Goldman Sachs has downgraded MoonLake Immunotherapeutics (MLTX) to Sell, highlighting the failed VELA-2 trial endpoint and persistent approval risks for its key drug, sonelokimab, despite a competing firm's more bullish outlook.
Africa's largest conglomerate secures a strategic gas supply agreement with Nigeria's state oil firm, a key move supporting national ambitions to leverage vast gas reserves for industrial growth and investment.
Marius Borg Høiby, the eldest son of Crown Princess Mette-Marit, was taken into custody on fresh allegations of assault and weapons offenses just days before his high-profile trial on multiple rape charges is set to begin, deepening the crisis for Norway's monarchy.
A deep dive into valuation metrics suggests Martin Marietta Materials (MLM) shares may be pricing in an overly optimistic outlook for construction growth, with key models indicating potential overvaluation.
Amid a market obsessed with artificial intelligence, investment firm Giverny Capital reveals a new position in Hawkins, Inc., a specialty chemicals manufacturer. We examine the rationale behind this contrarian bet and what it says about current market dynamics.
Nine men face prosecution for one of Nigeria's deadliest rural attacks in recent years, as authorities seek to demonstrate action on persistent security crises in the volatile Middle Belt region.
In a significant step toward reconciliation, Syrian interior ministry forces entered the Kurdish-administered city of al-Hassakeh on Monday. The move, part of a fragile new agreement with the Syrian Democratic Forces, aims to cement a ceasefire and outlines a path for the integration of Kurdish-led institutions into the state's security and administrative framework.
Quince Therapeutics' lead candidate, eDSP, has failed to meet primary and secondary endpoints in its pivotal Phase III NEAT trial for the rare neurological disorder Ataxia-Telangiectasia (A-T), triggering a catastrophic drop in the company's share price.
A convoy of Syrian government forces was observed moving toward the strategic northeastern city of Hasakah on Monday, implementing a ceasefire agreement that aims to reintegrate Kurdish-administered territories with Damascus.
Stifel Nicolaus lowered its price target on Altria Group (MO) by $4 to $68, citing higher-than-expected operating costs. Despite near-term headwinds, the firm reaffirmed its Buy rating, pointing to the tobacco giant's resilient dividend profile and long-term earnings guidance.
While the industrial sector has surged ahead of the broader market, not all companies are equally positioned for sustainable growth. We analyze one defense contractor with strong tailwinds and two manufacturers where valuation concerns loom large.
The industrial sector has outperformed the broader market, buoyed by regulatory shifts. However, not all companies are equally positioned. We analyze one stock with a durable edge and two facing potential headwinds.
While the industrial sector has surged ahead of the broader market, not all companies are positioned to weather an economic downturn. We examine three industrial stocks where valuation and business model concerns suggest investors should proceed with caution.
While often operating behind the scenes, industrial companies are the engine of the U.S. economy. Bolstered by a favorable interest rate environment, the sector has surged 18.8% in the last six months, significantly outpacing the S&P 500. We analyze two firms with durable competitive edges and one that may be losing momentum.
The Italian construction giant Webuild secures a major contract to build a critical section of the SS106 Jonica road, a project set to enhance connectivity in Calabria while creating hundreds of jobs and employing advanced construction technologies.
The Austrian government has granted a two-year renewal for the Wolfsberg lithium mining license, with a final decision on production expected by end-2026 as lithium prices rebound strongly.
Sanofi's experimental oral drug venglustat demonstrated significant neurological benefits for patients with Type 3 Gaucher disease in a late-stage trial, but failed to meet its primary endpoint in a separate study for Fabry disease, casting uncertainty on its regulatory path.
Aalberts N.V. (AMS:AALB), a mid-cap specialist in industrial technology, has seen a significant price surge on the ENXTAM, prompting analysts to revisit its valuation and growth trajectory amidst market volatility.
In a targeted night operation in Borno state, Nigerian troops neutralized a high-ranking Boko Haram leader and ten fighters, marking a significant blow to the militant group's command structure in its historic stronghold.
